The Ab27-based ADC exhibited dramatic antitumor activity in vitro and in a colon cancer xenograft model (S.K., unpublished data), suggesting that Ab27-based ADCs could serve as potent therapeutics for the treatment of TM4SF5+ cancers. This evidence concerns the gene TM4SF5 and malignant colon neoplasm.